Inspection Backlogs Post-COVID 2025

In the wake of COVID-19, global regulators are still working through substantial backlogs in pharmaceutical manufacturing site inspections. For the industry, these delays add uncertainty to supply chain planning, maintaining compliance, and anticipating regulatory measures. Using the QYOBO platform, we analysed more than 32,000 inspections and over 5,000 pharmaceutical manufacturing sites worldwide, revealing notable changes in the scale and frequency of regulatory oversight since 2020.